IMNM NASDAQ
Credit Risk of going bust: lower than 84% of companies Debt: 0.2% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down more than 99.9%), Immunome, Inc. would be worth roughly what it owes.
Total debt $4.6M against a stock market value of $2.11B.
Distance to default 10.98 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $2.3M (short-term plus half of long-term), stock volatility 61.0%; Altman Z'' 11.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Bothell, WA 98011
US
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Higgins Jack | S-Sale | 13,200 | $25.32 | 2026-09-11 |
| Higgins Jack | G-Gift | 8,800 | — | 2026-09-11 |
| Barchas Isaac | S-Sale | 11,048 | $27.25 | 2026-08-12 |
| Barchas Isaac | S-Sale | 62,291 | $26.23 | 2026-08-11 |
| Barchas Isaac | S-Sale | 10,125 | $26.07 | 2026-08-10 |